Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation

Table 3 Comparison of doses to pelvic bone marrow and its subsistes (defined with outer bone contours) and to inactive bone marrow and its subsites (defined with ¹⁸FDG-PET) among the 4 plans

		Plan A		Plan B		Plan C		Plan D		p ≤ 0.05 ANOVA	Fisher-Hayter test
Structure	Parameter	Mean	SD(+/−)	Mean	SD(+/−)	Mean	SD(+/−)	Mean	SD(+/−)
PBM	D _max	53.50	2.30	53.57	2.20	53.55	2.13	53.73	2.09	NS
PBM	D _mean	25.72	2.44	23.30	2.38	23.25	2.81	23.58	2.74	NS
LSBM	D _max	48.56	2.17	48.83	1.79	49.21	1.88	49.27	1.95	NS
LSBM	D _mean	30.88	3.68	26.44	3.85	26.52	3.97	26.97	3.80	0.038	A vs B and C
IBM	D _max	48.64	3.04	48.89	3.17	49.35	2.99	49.16	3.21	NS
	D _mean	22.16	1.59	21.57	1.48	20.48	2.31	20.84	2.38	NS
	V ₃₀	24.58	4.74	24.65	3.76	21.14	6.60	22.06	7.36	NS
	V ₄₀	7.13	3.03	6.34	2.75	6.65	2.42	7.18	2.70	NS
	V ₄₅	1.15	1.90	1.09	2.15	1.49	1.53	1.45	1.81	NS
LPBM	D _max	53.60	2.45	53.76	2.33	53.89	2.33	54.01	2.27	NS
LPBM	D _mean	25.99	4.12	23.76	4.36	24.46	4.62	24.60	4.48	NS
1- ^ACTPBM	D _max	53.38	2.25	53.38	2.12	53.36	2.05	53.55	2.09	NS
1- ^ACTPBM	D _mean	22.70	3.58	20.21	3.40	21.18	3.92	21.56	3.79	NS
1-^ACTLSBM	D _max	48.32	2.17	48.60	1.85	48.94	1.90	48.95	2.00	NS
1-^ACTLSBM	D _mean	28.95	4.43	24.00	4.88	25.12	3.93	25.83	3.74	NS
1-^ACTIBM	D _max	48.60	3.06	48.70	3.32	49.24	3.07	49.06	3.17	NS
1-^ACTIBM	D _mean	19.98	3.65	18.96	3.59	19.05	3.71	19.43	3.77	NS
1-^ACTLPBM	D _max	53.28	2.20	53.27	2.04	53.36	2.05	53.38	2.01	NS
1-^ACTLPBM	D _mean	21.85	4.16	19.60	3.88	20.77	4.82	21.06	4.60	NS

Legend: D _max maximal dose, D _mean mean dose, SD standard deviation, V _30,40,45 relative volume receiving 30,40,45 Gy, PBM pelvic bone marrow, LSBM lumbar-sacral bone marrow, IBM iliac bone marrow, LPBM lower pelvis bone marrow,^ACT active, A, B, C plan A, B, C, NS non significant

ISSN: 1471-2407